References
- Addiego, Jr. J. E., E. Gomperts, S. Liu, P. Bailey, S. G. Courter, M. L. Lee, G. G. Neslund, H. S. Kingdon, and M. J. Griffith. 1992. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography. Thromb. Haemost. 67: 19-27 https://doi.org/10.1055/s-0038-1648373
- Andrewes, C. 1989. Andrewes' Viruses of Vertebrates, pp. 120- 145. Balliere Tindal, London, U.K
- Berkman, S. A. 1988. Infectious complications of blood transfusion. Blood Rev. 2: 206-210 https://doi.org/10.1016/0268-960X(88)90026-4
- Boschetti, N., I. Niederhauser, C. Kempf, A. Stuhler, J. Lower, and J. Blumel. 2004. Different susceptibility of B19 virus and mice minute virus to low pH treatment. Transfusion 44: 1079-1086 https://doi.org/10.1111/j.1537-2995.2004.03420.x
- Burnouf, T. and M. Radosevich. 2000. Reducing the risk of infection from plasma products: Specific preventative strategies. Blood Rev. 14: 94-110. https://doi.org/10.1054/blre.2000.0129
- Carpenter, J. F., M. J. Pikal, B. S. Chang, and T. W. Randolph. 1997. Rational design of stable lyophilized protein formulations: Some practical advice. Pharm. Res. 14: 969-975 https://doi.org/10.1023/A:1012180707283
- Chudy, M., I. Budek, B. Keller-Stanislawski, K. A. McCaustland, S. Neidhold, B. H. Robertson, C. M. Nubling, R. Seitz, and J. Lower. 1999. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J. Med. Virol. 57: 91-99 https://doi.org/10.1002/(SICI)1096-9071(199902)57:2<91::AID-JMV1>3.0.CO;2-L
-
Dichtelmuller, H., D. Rudnick, B. Breuer, R. Kotitschke, M. Kloft, A. Darling, et al. 1996. Improvement of virus safety of a S/D treated factor VIII concentrate by additional dry heat treatment at
$100^{\circ}C$ . Biologicals 24: 125-130 https://doi.org/10.1006/biol.1996.0016 - Gummadi, S. N. 2003. What is the role of thermodynamics on protein stability? Biotechnol. Bioprocess Eng. 8: 9-18 https://doi.org/10.1007/BF02932892
- Hoyer, L. W. 1994. Hemophilia A. N. Engl. J. Med. 330: 38 https://doi.org/10.1056/NEJM199401063300108
- International Conference on Harmonisation. 1998. Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability. Federal Register 63: 51074-51084
- Jee, Y. M., U. Go, D. Cheon, Y. Kang, J. D. Yoon, S. W. Lee, et al. 2006. Detection of hepatitis A virus from clotting factors implicated as a source of HAV infection among haemophilia patients in Korea. Epidemiol. Infect. 134: 87-93 https://doi.org/10.1017/S0950268805004632
- Karber, J. 1931. Beitrag zur kollectiven Behandlung pharmakologische Reihenversuche. Arch. Exp. Path. Pharmak. 162: 480-483 https://doi.org/10.1007/BF01863914
- Kim, H., Y. Jee, H.-S. Mun, B.-C. Song, J.-H. Park, J.-W. Hyun, et al. 2007. Comparison of full genome sequences between two hepatitis B virus strains with or without preC mutation (A1896) from a single Korean hepatocellular carcinoma patient. J. Microbiol. Biotechnol. 17: 701-704
- Kim, I. S. 2003. Comparative inactivation of hepatitis A virus and murine encephalomyocarditis virus to various inactivation processes. Kor. J. Microbiol. 39: 242-247
- Kim, I. S., H. G. Eo, C. W. Park, C. E. Chang, and S. Lee. 2001. Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and pasteurization during the manufacture of albumin and immunoglobulins from human plasma. Biotechnol. Bioprocess Eng. 6: 25-30 https://doi.org/10.1007/BF02942246
- Kim, I. S., Y. W. Choi, and S. R. Lee. 2004. Optimization and validation of a virus filtration process for efficient removal of viruses from urokinase solution prepared from human urine. J. Microbiol. Biotechnol. 14: 140-147
- Kim, I. S., Y. W. Choi, S. R. Lee, and H. M. Sung. 2004. Cold ethanol fractionation and heat inactivation of hepatitis A virus during manufacture of albumin from human plasma. Biotechnol. Bioprocess Eng. 9: 57-60
- Kim, I. S., Y. W. Choi, S. R. Lee, H. S. Woo, and S. Lee. 2001. Removal and inactivation of viruses during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. Biotechnol. 11: 497-503
- Kim, I. S., Y. W. Choi, S. R. Lee, M. S. Lee, K. H. Huh, and S. Lee. 2001. Removal and inactivation of hepatitis A virus during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. 39: 67-73
- Kim, I. S., Y. W. Choi, S. R. Lee, Y. Kang, K. M. Lee, D. H. Park, H. S. Woo, and S. Lee. 2002. Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine. Biotechnol. Bioprocess Eng. 7: 340-346 https://doi.org/10.1007/BF02933518
- Klein, H. G. 2005. Pathogen inactivation technology: Cleansing the blood supply. J. Intern. Med. 257: 224-237 https://doi.org/10.1111/j.1365-2796.2005.01451.x
- Laub, R. and P. Strengers. 2002. Parvovirus and blood products. Pathol. Biol. (Paris) 50: 339-348 https://doi.org/10.1016/S0369-8114(02)00303-6
- Lemon, S. M. 1994. The natural history of hepatitis A: The potential for transmission by transfusion of blood or blood products. Vox Sang. 67(Suppl 4): 19-23 https://doi.org/10.1111/j.1423-0410.1994.tb04539.x
- Morgenthaler, J. J. 2000. New development in plasma fractionation and virus inactivation. Vox Sang. 78(Suppl 2): 217-221 https://doi.org/10.1046/j.1423-0410.2000.7840217.x
- Mosley, J. W. and J. Rakela. 1999. Foundling viruses and transfusion medicine. Transfusion 39: 1041-1044 https://doi.org/10.1046/j.1537-2995.1999.39101041.x
- Murgatroyd, K. 1997. The freeze drying process, pp. 1-58. In P. Cameron (ed.), Good Pharmaceutical Freeze-Drying Practice. Interpharm Press, IL, U.S.A
- Powell J. S., M. Bush, J. Harrison, C. Abildgaard, E. Vosburgh, A. R. Thompson, and D. Hurst. 2000. Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80oC terminal dry heat treatment in patients with haemophilia A. Haemophilia 6: 140-149 https://doi.org/10.1046/j.1365-2516.2000.00407.x
- Roberts, P. L. and H. Hart. 2000. Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates. Biologicals 28: 185-188 https://doi.org/10.1006/biol.2000.0256
- Robertson, B. H. and D. D. Erdman. 2000. Non-enveloped viruses transmitted by blood and blood products. Dev. Biol. Stand. 102: 29-35
- Robinson, S. M., H. Schwinn, and A. Smith. 1992. Clotting factors and hepatitis A. Lancet 340: 1465 https://doi.org/10.1016/0140-6736(92)92652-V
- Shin, J. S., Y. W. Choi, H. M. Sung, Y.-W. Ryu, and I. S. Kim. 2006. Enhanced virus safety of a solvent/detergent-treated antihemophilic factor IX concentrate by dry-heat treatment. Biotechnol. Bioprocess Eng. 11: 19-25 https://doi.org/10.1007/BF02931863
- Shin, K.-S., J. H. Lim, J.-H. Kim, H. Myung, and S.-W. Lee. 2006. Inhibition of the replication of hepatitis C virus replicon with nuclease-resistant RNA aptamers. J. Microbiol. Biotechnol. 16: 1634-1639
- Song, M.-S., Y. Joo, E. H. Lee, J.-Y. Shin, C.-J. Kim, K.-S. Shin, M. H. Sung, and Y. K. Choi. 2006. Genetic characterization of encephalomyocarditis virus isolated from aborted swine fetus in Korea. J. Microbiol. Biotechnol. 16: 1570-1576
- Tabor, E. 1999. The epidemiology of virus transmission by plasma derivatives: Clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 39: 1160-1168 https://doi.org/10.1046/j.1537-2995.1999.39111160.x